Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. Individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss.

The global short bowel syndrome management market is growing at a CAGR of 19.6% during the forecast period from 2023 to 2030. According to the National Organization for Rare Diseases (NORD) 2016 statistics, the global prevalence of short bowel syndrome (SBS) is 1 to 9 per 100,000 people. Currently, short bowel syndrome is managed by the usage of therapeutics and supplements. The drugs prescribed for the management of short bowel syndrome are gastric acid reducers, bile acid sequestrants, antibiotics, growth hormones, and glutamine among others. Increasing awareness of gastrointestinal disorders and rising demand for GLP-2 drugs in developed and developing nations are the major parameters driving the global short bowel syndrome management market. However, adverse side effects associated with the drugs restrains the market growth. Furthermore, orphan drug designation provided to short bowel syndrome has generated several opportunities for R&D activities in the market.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as pipeline analysis, market inclination insights and drivers, challenges, and opportunities assists the readers for understanding the ongoing trends in the global Short Bowel Syndrome market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global Short Bowel Syndrome market. This report concludes with company profiles section that highlights major information about the key players engaged in global Short Bowel Syndrome market. In-depth competitive environment analysis and historical years (2020) market size data are also provided in the report. 

Thus, the research study provides a holistic view of the global Short Bowel Syndrome market, offering market size and estimates for the period from 2023 to 2030, keeping in mind the above-mentioned factors.

GLP-2 currently holds the largest market

Short bowel syndrome is a group of complex diseases that occurs due to malfunction of a portion of small and/or large intestine. The individuals with short bowel syndrome exhibit poor absorption of nutrients such as water, fats, carbohydrates, vitamins, minerals and other vital elements which leads to malnutrition, weight loss. However, in some cases, short bowel syndrome can lead to severe, disabling and life-threatening complications. There is no particular cure to this disorder however surgical removal (resection) of half or more of the small intestine is effective. Short bowel syndrome can lead to Crohn’s disease, injury or trauma to the small intestine. Such complications are making a significant contribution to the growth of the short bowel syndrome market. On the basis of drug the market is segmented into GLP-2, glutamine, growth hormone and others. GLP-2 currently holds the largest market in terms of drug in the short bowel syndrome market as it is marketed in U.S. and Europe under the brand name Gattex and Revestive in Europe and another international market. The drugs currently holds orphan drug status, and the exclusivity of the drugs in the treatment of the short bowel syndrome would further draw huge revenue during the forecast period.

Asia Pacific will boom the market

For the purpose of this study, the global short bowel syndrome market is segmented into regional markets such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. North America held the largest market in the short bowel syndrome market with U.S. being the highest-grossing country. The major factor driving the U.S. short bowel syndrome market is the rising prescription of Gattex, which is the only approve drug in the U.S. Moreover, the increasing demand for growth hormones and glutamine are further driving the short bowel market in the U.S. Europe held the second-largest market as in the U.S., approximately 6,000-7,000 SBS patients are dependent on parenteral support with a similar prevalence in Europe. Revestive is the highest-grossing drug in Europe which is marketed by Shire, plc. Moreover, efficient reimbursement scenario in North America and Europe would further drive the market for short-bowel syndrome during the forecast period.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Short Bowel Syndrome market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Short Bowel Syndrome market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Short Bowel Syndrome market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Short Bowel Syndrome market?
• Which is the largest regional market for Short Bowel Syndrome market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Short Bowel Syndrome market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Short Bowel Syndrome market worldwide?